Premium
BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON‐BULKY HODGKIN LYMPHOMA: AN UPDATE FROM a PHASE 2 CLINICAL TRIAL
Author(s) -
Park S.I.,
Olajide O.,
Reddy N.M.,
Budde L.E.,
Ghosh N.,
Richards K.L.,
Deal A.M.,
Noe J.F.,
Shea T.C.,
Ansell S.M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_69
Subject(s) - abvd , medicine , brentuximab vedotin , radiation therapy , dacarbazine , neutropenia , stage (stratigraphy) , surgery , chemotherapy , oncology , lymphoma , hodgkin lymphoma , vincristine , cyclophosphamide , paleontology , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom